

Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)

NCT06999902

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Praxis Precision Medicines
Enrollment	230 participants

Key Eligibility Criteria

Inclusion (2)

- A diagnosis of focal onset epilepsy according to the International League Against Epilepsy (ILAE) Classification of Epilepsy.
- Past evidence by computed tomography (CT) or magnetic resonance imaging (MRI) that has ruled out a progressive cause of epilepsy in the judgement of the investigator and/or in consultation with the medical monitor.

Exclusion (9)

- Subject has had any of the of the following within the 12-month period preceding trial entry: History of pseudo or psychogenic seizures, cluster seizures where the individual seizures cannot be counted, an episode of convulsive status epilepticus requiring hospitalization and intubation, or subject only has focal seizures with awareness that do not have motor activity.
- Planned epilepsy surgery during the course of the clinical trial.
- History of neurosurgery for seizures <1 year prior to enrollment, or radiosurgery <2 years prior to enrollment or vagus nerve stimulation (VNS) implantation.
- History of schizophrenia, obsessive-compulsive disorder, or other serious mental health disorders.
- History of malignancy, myeloproliferative or lymphoproliferative disorders within the past 5 years are excluded.

... and 4 more (see full listing online)

Locations (26 total)

Praxis Research Site, Phoenix, Arizona, United States
Praxis Research Site, DeLand, Florida, United States
Praxis Research Site, Miami Lakes, Florida, United States
... and 23 more locations